Ongoing Research Aims to Fill Gaps in Myelofibrosis Care

In this discussion, Kapila Viges, of the MPN Research Foundation, and John Mascarenhas, MD, of the Icahn School of Medicine, explore the latest advancements in myelofibrosis treatment. Modern clinical trials are investigating novel drug combinations with ruxolitinib and other JAK inhibitors to improve patient outcomes. One key study, the Phase III SENTRY trial, aims to evaluate the potential benefits of these emerging therapies. Watch as Viges and Dr. Mascarenhas provide expert insights into the evolving landscape of myelofibrosis research and treatment strategies.